Developer docs
API playgroundTry for free, no card

Search company profiles

Formulex

Full company profile

uuid002n649

Namestring
Formulex
Legal namestring
Formulex LTD
Websiteurl
formulex-pi.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Formulex is a privately held Israeli pharmaceutical contract development and analytical services company headquartered in the Weizmann Science Park, Ness Ziona, established in April 2019 as a continuation of SoluBest Ltd.'s activities in nano-technology based drug delivery and formulation. The company operates a single integrated facility offering formulation development, full analytical and bioanalytical support, and GMP-compliant manufacturing for clinical Phase 1 and Phase 2 supply, targeting pharmaceutical, biotech, nutraceutical, agrochemical, foodtech, and hospital clients in Israel and internationally.

Formulex's core technology platform comprises three patented delivery systems: SOLUMER® (solid dispersion via proprietary spray drying for oral bioavailability enhancement of insoluble-lipophilic compounds), OMEXA® (sublingual transmucosal delivery for faster onset and improved permeability), and NASAX® (intranasal nose-to-brain delivery that bypasses the blood-brain barrier via uniform spherical API particles). These are applied across dosage forms including oral, topical/transdermal, injectable micro-emulsions, inhalation sprays and dry powders, ophthalmic/otic, and rectal/vaginal formulations. The company has developed more than 10 medical cannabis products using SOLUMER and generic technologies, with five in clinical and commercial stages; SOLU-CBD demonstrates a 10x improvement in CBD aqueous solubility with six-month beverage stability.

Revenue is generated primarily through project-based contract formulation and analytical services — development agreements with global and Israeli pharma, biotech, nutraceutical, and agrochemical clients, complemented by clinical-phase GMP manufacturing fees. The go-to-market relies on direct enterprise sales, the corporate website, and conference participation (including Biomed 2023). The company is ISO 9001 certified (extended July 2023), holds a granted patent portfolio across its three core platforms, and is led by the inventor-founders of the technology alongside a board with deep Israeli biopharma venture capital and clinical expertise.

Short descriptiontext

Formulex is an Israeli CDMO providing GMP-compliant formulation development, analytical services, and clinical Phase 1/2 manufacturing built on patented SOLUMER, OMEXA, and NASAX drug delivery technologies, serving pharma, biotech, nutraceutical, agrochemical, and medical cannabis clients globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNess Ziona, Israel
HQ citystring
Ness Ziona
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical formulation services, drug delivery technologies, analytical testing services, medical cannabis products, contract development services
Industry3 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Formulation Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Contract Formulation Development Services
TypeProfessional Services
Description

Project-based contract services for drug formulation development, including oral, topical, and inhaled dosage forms for clinical phases one and two under GMP conditions. Revenue generated through development agreements with pharmaceutical, biotech, nutraceutical, and agrochemical companies.

formulex-pi.com
2Analytical and Bioanalytical Services
TypeProfessional Services
Description

Full analytical support including method development, validation, stability testing, and quality control services accompanying formulation development projects.

formulex-pi.com
3Medical Cannabis Product Development
TypeProfessional Services
Description

Development services for medical cannabis products using proprietary Solumer™ technology and generic technologies, with five products in clinical and commercial stages.

formulex-pi.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1SOLUMER
Description

A proprietary bioavailability enhancing technology based on interaction of insoluble-lipophilic molecules with polymers resulting in solid compositions that enhance drug bioavailability when in aqueous media.

formulex-pi.com
+2 more records
Core offering1 text field

Formulex is a contract formulation development and analytical services provider specializing in nano-technology based drug delivery. The company offers proprietary delivery platforms (SOLUMER® oral, OMEXA® sublingual, NASAX® intranasal) alongside full formulation development for clinical phase one and two studies under GMP conditions, comprehensive analytical/bioanalytical testing, and a portfolio of medical cannabis products built on the Solumer™ technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 10x improvement in CBD solubility (from 0.012 mg/ml to 0.12 mg/ml)
+2 more records
Product overview1 text field

Formulex is a pharmaceutical formulation and analytical services company offering a unified portfolio of proprietary drug delivery technologies and contract services. The core technology platform consists of three patented delivery systems: SOLUMER® (solid dispersion via spray drying for enhanced oral bioavailability), OMEXA® (sublingual transmucosal delivery), and NASAX® (intranasal brain delivery). These are complemented by a comprehensive suite of formulation development services covering topical, oral, injectable, inhalation, and ophthalmic dosage forms, alongside full analytical and bioanalytical testing capabilities. The company also develops medical cannabis products including SOLU-CBD and various cannabinoid delivery formulations. All services are supported by GMP-compliant production for clinical phases one and two.

Product and service1 record
1SOLUMER®
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large global CDMO offering bioavailability and formulation development services (including OptiMelt hot-melt extrusion and spray drying) for clinical and commercial phases. Competes with Formulex on complex-molecule projects but at far greater scale.

TypeDirect peer
Description

UK-based CDMO specializing in integrated formulation development, manufacturing, and clinical testing for small-molecule drug programs. Mirrors Formulex's combined formulation + analytical + GMP clinical-phase model.

TypeDirect peer
Description

Portuguese specialty CDMO with deep expertise in spray-dried solid dispersions and bioavailability enhancement, serving the same pharma/biotech clients facing poorly soluble APIs. Closest functional analog to Formulex's SOLUMER-led offering.

TypeDirect peer
Description

Clinical-phase CDMO focused on oral, topical, and inhaled dosage forms with integrated analytical support — same clinical-phase I/II focus and dosage-form portfolio as Formulex.

TypeDirect peer
Description

US specialty CDMO offering formulation development, analytical services, and GMP manufacturing for clinical phases I/II — closely matching Formulex's service scope and customer profile.

TypeDirect peer
Description

Drug delivery and formulation company focused on cannabinoid and pharmaceutical products using proprietary thin-film and encapsulation technologies. Most direct peer for Formulex's medical cannabis product line.

7Evonik (Pharma Solutions)
TypeBroad incumbent
Description

Specialty chemicals incumbent supplying functional excipients, drug delivery technologies, and CDMO services including bioavailability enhancement. Broader portfolio but directly relevant for solubility/bioavailability customers.

TypeBroad incumbent
Description

Global CDMO offering end-to-end pharmaceutical development and manufacturing services, including formulation for small molecules and clinical/commercial supply. Dominant incumbent against which Formulex competes for biotech formulation projects.

9Lubrizol Life Science Health
TypeDirect peer
Description

CDMO division of Lubrizol providing bioavailability-enhancing excipients and formulation services, including spray-dried dispersions. Directly competes for the same difficult-to-formulate API projects.

10Avomeen
TypeDirect peer
Description

US contract laboratory and formulation services provider combining analytical, bioanalytical, and formulation development. Comparable boutique scale and integrated service offering to Formulex.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Formulex

Pharmaceutical Contract Formulation Servicesformulex-pi.com

Formulex is an Israeli CDMO providing GMP-compliant formulation development, analytical services, and clinical Phase 1/2 manufacturing built on patented SOLUMER, OMEXA, and NASAX drug delivery technologies, serving pharma, biotech, nutraceutical, agrochemical, and medical cannabis clients globally.

What Formulex does

Formulex is a privately held Israeli pharmaceutical contract development and analytical services company headquartered in the Weizmann Science Park, Ness Ziona, established in April 2019 as a continuation of SoluBest Ltd.'s activities in nano-technology based drug delivery and formulation. The company operates a single integrated facility offering formulation development, full analytical and bioanalytical support, and GMP-compliant manufacturing for clinical Phase 1 and Phase 2 supply, targeting pharmaceutical, biotech, nutraceutical, agrochemical, foodtech, and hospital clients in Israel and internationally.

Formulex's core technology platform comprises three patented delivery systems: SOLUMER® (solid dispersion via proprietary spray drying for oral bioavailability enhancement of insoluble-lipophilic compounds), OMEXA® (sublingual transmucosal delivery for faster onset and improved permeability), and NASAX® (intranasal nose-to-brain delivery that bypasses the blood-brain barrier via uniform spherical API particles). These are applied across dosage forms including oral, topical/transdermal, injectable micro-emulsions, inhalation sprays and dry powders, ophthalmic/otic, and rectal/vaginal formulations. The company has developed more than 10 medical cannabis products using SOLUMER and generic technologies, with five in clinical and commercial stages; SOLU-CBD demonstrates a 10x improvement in CBD aqueous solubility with six-month beverage stability.

Revenue is generated primarily through project-based contract formulation and analytical services — development agreements with global and Israeli pharma, biotech, nutraceutical, and agrochemical clients, complemented by clinical-phase GMP manufacturing fees. The go-to-market relies on direct enterprise sales, the corporate website, and conference participation (including Biomed 2023). The company is ISO 9001 certified (extended July 2023), holds a granted patent portfolio across its three core platforms, and is led by the inventor-founders of the technology alongside a board with deep Israeli biopharma venture capital and clinical expertise.

Formulex firmographics

Firmographics
Name
Formulex
Legal name
Formulex LTD
Website
https://formulex-pi.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Formulex is an Israeli CDMO providing GMP-compliant formulation development, analytical services, and clinical Phase 1/2 manufacturing built on patented SOLUMER, OMEXA, and NASAX drug delivery technologies, serving pharma, biotech, nutraceutical, agrochemical, and medical cannabis clients globally.
Ownership category
akta.pro rank

Formulex industry classification

Industry
Product category
Pharmaceutical Contract Formulation Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical formulation services
  • Drug delivery technologies
  • Analytical testing services
  • Medical cannabis products
  • Contract development services

Where Formulex is headquartered

Location

Headquarters

HQ city
Ness Ziona
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Formulex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Formulation Development Services: Project-based contract services for drug formulation development, including oral, topical, and inhaled dosage forms for clinical phases one and two under GMP conditions. Revenue generated through development agreements with pharmaceutical, biotech, nutraceutical, and agrochemical companies.
  2. Analytical and Bioanalytical Services: Full analytical support including method development, validation, stability testing, and quality control services accompanying formulation development projects.
  3. Medical Cannabis Product Development: Development services for medical cannabis products using proprietary Solumer™ technology and generic technologies, with five products in clinical and commercial stages.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Formulex product offering

Product offering

Core offering

Formulex is a contract formulation development and analytical services provider specializing in nano-technology based drug delivery. The company offers proprietary delivery platforms (SOLUMER® oral, OMEXA® sublingual, NASAX® intranasal) alongside full formulation development for clinical phase one and two studies under GMP conditions, comprehensive analytical/bioanalytical testing, and a portfolio of medical cannabis products built on the Solumer™ technology.

Product overview

Formulex is a pharmaceutical formulation and analytical services company offering a unified portfolio of proprietary drug delivery technologies and contract services. The core technology platform consists of three patented delivery systems: SOLUMER® (solid dispersion via spray drying for enhanced oral bioavailability), OMEXA® (sublingual transmucosal delivery), and NASAX® (intranasal brain delivery). These are complemented by a comprehensive suite of formulation development services covering topical, oral, injectable, inhalation, and ophthalmic dosage forms, alongside full analytical and bioanalytical testing capabilities. The company also develops medical cannabis products including SOLU-CBD and various cannabinoid delivery formulations. All services are supported by GMP-compliant production for clinical phases one and two.

Differentiator

Problem solved

Functional benefit

Brands

  • SOLUMER: A proprietary bioavailability enhancing technology based on interaction of insoluble-lipophilic molecules with polymers resulting in solid compositions that enhance drug bioavailability when in aqueous media.
  • OMEXA
  • NASAX

Products and services

  • SOLUMER®

Quantifiable outcome

  • 10x improvement in CBD solubility (from 0.012 mg/ml to 0.12 mg/ml)
  • +2 more outcomes

Companies that use Formulex

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Formulex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Formulex partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves7 records

Expansion highlights2 records

Formulex competitors and assessment

Company assessment

Broad incumbents

  • Catalent: Large global CDMO offering bioavailability and formulation development services (including OptiMelt hot-melt extrusion and spray drying) for clinical and commercial phases. Competes with Formulex on complex-molecule projects but at far greater scale.
  • Evonik (Pharma Solutions): Specialty chemicals incumbent supplying functional excipients, drug delivery technologies, and CDMO services including bioavailability enhancement. Broader portfolio but directly relevant for solubility/bioavailability customers.
  • Thermo Fisher Scientific (Patheon): Global CDMO offering end-to-end pharmaceutical development and manufacturing services, including formulation for small molecules and clinical/commercial supply. Dominant incumbent against which Formulex competes for biotech formulation projects.

Direct peers

  • Quotient Sciences: UK-based CDMO specializing in integrated formulation development, manufacturing, and clinical testing for small-molecule drug programs. Mirrors Formulex's combined formulation + analytical + GMP clinical-phase model.
  • Hovione: Portuguese specialty CDMO with deep expertise in spray-dried solid dispersions and bioavailability enhancement, serving the same pharma/biotech clients facing poorly soluble APIs. Closest functional analog to Formulex's SOLUMER-led offering.
  • Halo Pharma: Clinical-phase CDMO focused on oral, topical, and inhaled dosage forms with integrated analytical support — same clinical-phase I/II focus and dosage-form portfolio as Formulex.
  • Alcami: US specialty CDMO offering formulation development, analytical services, and GMP manufacturing for clinical phases I/II — closely matching Formulex's service scope and customer profile.
  • CURE Pharmaceutical: Drug delivery and formulation company focused on cannabinoid and pharmaceutical products using proprietary thin-film and encapsulation technologies. Most direct peer for Formulex's medical cannabis product line.
  • Lubrizol Life Science Health: CDMO division of Lubrizol providing bioavailability-enhancing excipients and formulation services, including spray-dried dispersions. Directly competes for the same difficult-to-formulate API projects.
  • Avomeen: US contract laboratory and formulation services provider combining analytical, bioanalytical, and formulation development. Comparable boutique scale and integrated service offering to Formulex.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Formulex social profiles

Digital presence

Formulex compliance and trust

Trust signal

Compliance1 record

Formulex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Formulex leadership team

Management profile

Number of profiles

Profiles7 records

Formulex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Formulex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Formulex

What does Formulex do?

Formulex is a contract formulation development and analytical services provider specializing in nano-technology based drug delivery. The company offers proprietary delivery platforms (SOLUMER® oral, OMEXA® sublingual, NASAX® intranasal) alongside full formulation development for clinical phase one and two studies under GMP conditions, comprehensive analytical/bioanalytical testing, and a portfolio of medical cannabis products built on the Solumer™ technology.

Is Formulex a public or private company?

Formulex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Formulex founded?

Formulex was founded in 2019. It employs 1 to 10 people.

Where is Formulex based?

Formulex is headquartered in Ness Ziona, Israel, in the Middle East region.

How does Formulex make money?

Three revenue lines are on record. Contract Formulation Development Services are the primary driver. The others are analytical and Bioanalytical Services and medical Cannabis Product Development.

Who are Formulex's main competitors?

Broad incumbents on record are Catalent, Evonik (Pharma Solutions) and Thermo Fisher Scientific (Patheon). Direct peers are Quotient Sciences, Hovione, Halo Pharma, Alcami, CURE Pharmaceutical, Lubrizol Life Science Health and Avomeen.

Does Formulex have an API?

No public API is recorded for Formulex.

What industry is Formulex in?

Formulex's product category is Pharmaceutical Contract Formulation Services. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales